Clinical trial
A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)
NCT01678105 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)
- Lead sponsor
- Ontario Clinical Oncology Group (OCOG)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- September 30, 2015
- Enrollment
- 21 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
acc, metastatic adenoid cystic carcinoma of the salivary glands, recurrent adenoid cystic carcinoma of the salivary glands, salivary gland cancers